Internet Explorer is no longer supported by Microsoft. To browse the NIHR site please use a modern, secure browser like Google Chrome, Mozilla Firefox, or Microsoft Edge.

Trial finds new CAR T-cell therapy is effective at killing cancer cells

Published: 10 January 2022

Early stage research suggests a new version of an immunotherapy called CAR T-cell therapy has fewer toxic side effects and is effective for longer in adults with relapsed B-cell acute lymphoblastic leukaemia (B-ALL), a group who previously had few treatment options available.

There is currently no approved ‘curative’ treatment available for adult patients with relapsed B-ALL. Current treatment is with chemotherapy and the prognosis for these patients is poor.

CAR T-cell therapy programmes immune T-cells specifically to target cancer cells. However, current CAR T-cell therapies have limitations.

Chief Investigator Professor Karl Peggs, Director of the Sir Naim Dangoor Centre for Cellular Immunotherapy at UCLH, explained: “The immune system can become over-activated by the therapy causing a toxic reaction called ‘cytokine release syndrome’. Another consequence of this over-activation is that the engineered T-cells become immunologically exhausted and no longer persist in the patient’s body. This can allow the cancer to relapse.

“These problems are particularly difficult in adults with relapsed B-ALL and consequently there is no licensed CAR T-cell therapy for adults for this type of cancer.”

Creating a second-generation CAR T-cell therapy

To overcome these issues, the new therapy was designed to bind leukemic cells less tightly and for shorter periods of time than other T-cell therapies. 

The scientists hoped this second-generation design would reduce cytokine release syndrome toxicity and allow the CAR T-cells to live in the patients for longer to prevent relapse.

A Phase 1 clinical trial funded by the NIHR Invention for Innovation (i4i) programme and supported by the NIHR UCLH Biomedical Research Centre (BRC) tested this new CAR T-cell therapy in patients. In the trial 20 adult patients with relapsed B-ALL had their T-cells genetically modified to target their cancer cells.

None of the patients had cytokine release syndrome, and the CAR T-cell levels remained high in patients, with persistence evident in three-quarters of patients for around 6 months.

One month after treatment, 85% of the patients were in complete remission. Furthermore, with persistence of the therapeutic cells, half remained in remission after a year. The results have been published in the Journal of Clinical Oncology.

Trial investigator, Associate Professor at UCL Cancer Institute and consultant haematologist at UCLH, Dr Claire Roddie, said: “This new type of CD19 CAR is designed for faster interactions with cancerous cells.

“The results show that the new design allows for the safe treatment with CAR T-Cell therapy to adult patients with relapsed B-ALL. Moreover, this treatment may allow patients to have long-term remissions with no other treatment.”

After the success of this trial, Autolus Therapies, a spin-off company from NIHR UCLH BRC, has initiated the next phase of research, assessing the therapy in 100 adults with relapsed B-ALL in Europe and the United States. This trial will evaluate the response rate to the therapy as well as duration of response and safety.

'I'm so glad that I was able to take part in the trial'

Claire Evans was diagnosed with B-ALL in 2015 and initially went into remission after treatment. In 2019, her leukaemia returned and she was referred to UCLH for inclusion on the CAR T-cell trial.

As of November 2021, it has been 24 months since her CAR T-cell therapy and she remains in remission.

Claire said: “When I relapsed in 2019 the doctors initially treated me with chemotherapy before one of them mentioned CAR-T and I was referred to UCLH who assessed me for participation in their clinical trial.

“As I was deemed suitable, I was able to start CAR-T treatment fairly quickly. Fortunately for me, I didn't have any adverse effects from the therapy.

“I'm so glad that I was able to take part in the trial, it has made all the difference and I'm still here. The initial results from my latest biopsy show no evidence of disease.”

Latest news